Metagenomi Therapeutics (MGX) Research & Development (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Research & Development data on file, last reported at $19.3 million in Q1 2026.

• Research & Development for Q1 2026 came in at $19.3 million, down 23.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $88.6 million (down 13.89% YoY), and the FY2025 annual result was $94.4 million, down 13.51% from the prior year.
• Research & Development declined to $19.3 million in Q1 2026 per MGX's latest filing, from $21.5 million in the prior quarter.
• Over five years, Research & Development peaked at $31.4 million in Q1 2024 and troughed at $19.3 million in Q1 2026.
• A 4-year average of $24.4 million and a median of $24.8 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2024 and 2026: Research & Development soared 56.18% in 2024, then retreated 23.24% in 2026.
• A 4-year view of Research & Development shows it stood at $24.8 million in 2023, then fell by 6.43% to $23.2 million in 2024, then fell by 7.18% to $21.5 million in 2025, then declined by 10.24% to $19.3 million in 2026.
• Business Quant data shows MGX's Research & Development at $19.3 million in Q1 2026, $21.5 million in Q4 2025, and $25.3 million in Q3 2025.